(7R)-4,7-二羟基-N,N,N-三甲基-10-氧代-3,5,9-三氧杂-4-磷杂十九碳-1-铵内盐4-氧化物 | 22248-63-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: (7R)-4,7-二羟基-N,N,N-三甲基-10-氧代-3,5,9-三氧杂-4-磷杂十九碳-1-铵内盐4-氧化物
• 英文名称: 1-Decanoyl-sn-glycero-3-phosphocholine
• 英文别名: [(2R)-3-decanoyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 22248-63-1
• 化学式: C18H38NO7P
• 分子量: 411.5
• InChiKey: SECPDKKEUKDCPG-QGZVFWFLSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 海关编码：
  2923900090

反应信息

• 作为反应物：
  描述：

  (7R)-4,7-二羟基-N,N,N-三甲基-10-氧代-3,5,9-三氧杂-4-磷杂十九碳-1-铵内盐4-氧化物 、 水 生成 1-Decanoyl-sn-glycero-3-phosphate(2-) 、 胆碱 、 氢(+1)阳离子
  参考文献：
  名称：

  Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase

  摘要：

  We purified human plasma lysophospholipase D that produces physiologically active lysophosphatidic acid and showed that it is a soluble form of autotaxin, an ecto-nucleotide pyrophosphatase/phosphodiesterase, originally found as a tumor cell motility-stimulating factor. Its lower K-m value for a lysophosphatidylcholine than that for a synthetic substrate of nucleotide suggests that lysophosphatidylcholine is a more likely physiological substrate for autotaxin and that its predicted physiological and pathophysiological functions could be mediated by its activity to produce lysophosphate acid, an intercellular mediator. Recombinant autotaxin was found to have lysophospholipase D activity; its substrate specificity and metal ion requirement were the same as those of the purified plasma enzyme. The activity of lysophospholipase, D for exogenous lysophosphatidylcholine in human serum was found to increase in normal pregnant women at the third trimester of pregnancy and to a higher extent in patients in threatened preterm delivery, suggesting its roles in induction of parturition.

  DOI：

  10.1074/jbc.m205623200

文献信息

• US5308766A
  申请人：——

  公开号：US5308766A

  公开（公告）日：1994-05-03
• US5352673A
  申请人：——

  公开号：US5352673A

  公开（公告）日：1994-10-04
• US5427919A
  申请人：——

  公开号：US5427919A

  公开（公告）日：1995-06-27
• US5567597A
  申请人：——

  公开号：US5567597A

  公开（公告）日：1996-10-22
• [EN] NOVEL PHOSPHOLIPASE A2 INHIBITORS
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：WO1992022289A1

  公开（公告）日：1992-12-23

  (EN) The present invention provides prodrugs that serve as useful therapeutics for various disease states and conditions mediated by underlying specific hydrolytic enzyme activity. The prodrugs hereof (additionally) impart a physiologically bioactive component thus providing prodrug compounds that are capable of imparting dual effect systemically.(FR) La présente invention se rapporte à des promédicaments qui peuvent être utilisés comme agents thérapeutiques pour différents états pathologiques et états induits par une activité enzymatique hydrolytique et spécifique sous-jacente. Les promédicaments décrits ici confèrent en outre une composante physiologiquement bioactive, ce qui permet d'obtenir des composés de promédicaments capables de produire un double effet sur l'organisme.